Latest news with #MHSRS
Business Wire
3 days ago
- Business
- Business Wire
Tivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, is proud to announce it advanced discussions with key US Government agencies through its participation in the 2025 Military Health System Research Symposium (MHSRS), held August 4-7, 2025, in Kissimmee, Florida. The MHSRS is the Department of Defense's premier scientific meeting that brings together military, academic, and industry experts to discuss medical research and innovation in support of warfighter health and readiness. Direct Access to DoD Decision-Makers and Researchers MHSRS provides direct access to organizations seeking military partnerships and connects companies with key funding organizations. Tivic's President of Biopharma and Chief Operating Officer, Michael Handley, met with key members of the Biomedical Advanced Research and Development Authority (BARDA), the Armed Forces Radiobiology Research Institute (AFRRI) and the Medical CBRN Defense Consortium (MCDC) to discuss potential pathways to deploy Entolimod as a military countermeasure. BARDA's mission is to develop medical countermeasures that address the public health and medical consequences of chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks, pandemic influenza, and emerging infectious diseases. AFRRI's mission is to defend the Nation from nuclear and radiological threats through research, leadership, training, and education. The MCDC was formed in response to the US Government's expressed interest to engage and fund advanced development efforts to support the Department of Defense's (DoD) medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel. 'It was an honor to contribute to the vital conversations that were focused generally on radiation medical countermeasures, and specifically on our lead clinical product candidate, Entolimod, which has the potential to protect the warfighter in the instance that they are exposed to radiation,' said Handley. Representatives from Tivic joined global thought leaders, military leaders and researchers to share insights, explore collaborative opportunities, and present ongoing research intended to improve health outcomes for warfighters exposed to radiation in the field. About MHSRS MHSRS serves as a dynamic platform for the exchange of research findings across multiple disciplines, including combat casualty care, medical countermeasures, infectious disease, and mental health. The symposium fosters collaboration among business leaders, scientists, clinicians, and policymakers, ensuring innovations reach those who serve as quickly and effectively as possible. About Tivic Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late stage development. Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities, as well as interactions with governmental agencies, such as BARDA, the AFRRI and the MCDC; changes to the company's relationship with the its partners; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; timing and success of clinical trials and study results; regulatory requirements and pathways for approval; consummation of any strategic transactions; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors," as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
Business Wire
16-07-2025
- Health
- Business Wire
Humanetics Corporation to Present at Upcoming Military Medical and Defense Conferences
MINNEAPOLIS--(BUSINESS WIRE)--Humanetics Corporation, an advanced clinical-stage specialty pharmaceutical company pioneering novel prophylactic Medical Countermeasures for warfighters, first responders, and others at risk of radiation exposure from nuclear attacks or industrial accidents, today announced that Company scientists and members of the leadership team will be presenting and participating at the following conferences and events: Humanetics to present key updates on BIO 300 at multiple high-profile upcoming events. Share Countering Weapons of Mass Destruction (CWMD) Consortium/Medical CBRN Defense Consortium (MCDC) Annual Membership Meeting – July 23-24, 2025 – Baltimore, MD This conference brings together medical countermeasures, protective technologies, and cutting-edge diagnostics to bridge the gap between biotechnology and real-world threat mitigation Anna Kellner, Ph.D., of Humanetics will be presenting on July 23, 2025, as part of the Health Security Innovation Challenge Military Health System Research Symposium (MHSRS) – August 4-7, 2025 – Kissimmee, FL This conference provides a collaborative setting for the exchange of information between military providers with deployment experience, research and academic scientists, international partners, and industry on research and related military health care initiatives Artur Serebrenik, Ph.D. of Humanetics will deliver a podium presentation on August 4, 2025, covering updates on the development of BIO 300 as a prophylactic Medical Countermeasure Prophylactic Medical Countermeasures for the U.S. Warfighter: Radiation, Risks, and Readiness – August 12, 2025 A Virtual Panel Discussion Register here: This virtual panel will explore the state of play in radiation Medical Countermeasures The panel will feature scientific, clinical, and military medicine subject matter experts Fed Supernova – August 19-21, 2025 – Austin, TX This conference connects entrepreneurs, government, and industry to collaborate on dual-use solutions that put commercial technology in the hands of the U.S. Department of Defense Humanetics will be engaging with stakeholders and providing updates on BIO 300 Radiation Research Society 71st Annual Meeting – September 21-24, 2025 – San Juan, Puerto Rico This meeting highlights cutting edge topics at the forefront of radiation research, including novel radiation-based treatment approaches and standards for precision medicine, applications and development of large-scale facilities for ion therapy, the impact and use of AI in radiation science, advances in multi-scale modeling, dosimetry and biodosimetry, the intersection of immunology and radiation effects, current strategies for the development of medical countermeasures, and emerging needs in radiation research, from fusion to space travel Michael Kaytor, Ph.D. of Humanetics will deliver a podium presentation on September 21, 2025, covering the use of biomarkers to support BIO 300 human dose translation for pre-exposure prophylaxis (PrEP) against Acute Radiation Syndrome About Humanetics Corporation Humanetics Corporation is an advanced clinical-stage specialty pharmaceutical company engaged in the accelerated discovery, development, and commercialization of proprietary drugs in markets with urgent and unmet needs with a focus on radiation modulators for oncology and medical countermeasures. For more information, visit
